April 17, 2014 7:23 AM ET

Pharmaceuticals

Company Overview of CeeTox, Inc.

Company Overview

As of January 1, 2014, CeeTox, Inc. was acquired by Apredica, Inc.. CeeTox, Inc., a contract research organization, focuses on in vitro toxicity screening of new drug candidates, chemicals, cosmetics, and consumer products. The company provides CTOX Panel for early toxicity testing; Acute Toxicity Screen, a cell-based system that identifies compounds, which produce acute toxicity; and Drug-Drug Interaction Toxicity Screen for identifying potential toxicity related to cytochrome P450 induction, inhibition, and metabolic activation. It also offers CardioTox Panel, an evaluation of cardiac toxicity; DermoTox, an in vitro screening for dermal corrosion, irritation, and custom evaluations using 3...

4717 Campus Drive

Suite 500

Kalamazoo, MI 49008

United States

Founded in 2003

Phone:

269-353-5555

Fax:

269-544-1077

Key Executives for CeeTox, Inc.

CeeTox, Inc. does not have any Key Executives recorded.

CeeTox, Inc. Key Developments

CeeTox, Inc. and Cellular Dynamics International, Inc. Collaborate to Offer Predictive in Vitro Test for Cardiotoxicity Using Human iPSC-derived Cells

CeeTox and Cellular Dynamics International announced the introduction of a new, highly predictive cardiac safety screening service that utilizes human induced pluripotent stem (iPS) cell-derived cardiomyocytes. The Cardiac Arrhythmia Assessment Screen(TM) (CAAS) combines CeeTox's expertise with in vitro toxicity screening and CDI's iCell(R) Cardiomyocytes to provide a comprehensive profile of drug-induced cardiac toxicity early in the drug development cycle. Cardiotoxicity is the cause for late-stage drug attrition and market withdrawal, and the FDA mandates cardiotoxic safety data on drug candidates prior to entering clinical development. Currently used animal models, non-cardiac cell lines transformed to mimic heart cells, and cadaveric cells do not truly recapitulate human response and are therefore more likely to miss adverse side effects. CDI's iCell Cardiomyocytes are highly pure, fully functional human cardiac cells derived from induced pluripotent stem cells (iPSCs). They are manufactured in reproducibly high quality and quantity to provide a more reliable, relevant and predictive in vitro model. CeeTox's CAAS provides a fast, real-time assessment of drug-induced cardiac arrhythmias and biochemical cytotoxicity, thus enabling researchers to monitor both acute and longer-term effects, in contrast to the single time point results obtained with other assays.

Similar Private Companies By Industry

Company Name Region
Targa Therapeutics Corporation United States
Tego BioSciences Corporation United States
DexGen Pharmaceuticals, Inc. United States
AnazaoHealth United States
Berkeley Bio-Organic Research Laboratories United States

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
January 2, 2014
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CeeTox, Inc., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.